5th Apr 2005 07:00
Dechra Pharmaceuticals PLC05 April 2005 Issued by Citigate Dewe Rogerson Limited, BirminghamDate: Tuesday 5th April 2005 Embargoed: 7.00am Dechra Pharmaceuticals PLC Dechra acquires veterinary licenses for critical care fluids Dechra Pharmaceuticals PLC ("Dechra" or the "Group") today announces that it hasacquired the licenses and goodwill for the UK and Eire in respect of the Vetivexrange of veterinary licensed products used for fluid therapy from GambroNorthern Ireland Limited, a division of the Gambro BCT, Inc. organisation and asubsidiary of Gambro AB. Gambro BCT, Inc. is a business area within Gambro AB,which is a leading international medical technology and healthcare company. The Vetivex critical care sterile fluid range administered by intravenousinfusion is used to address dehydration, electrolyte imbalance and metabolicacidosis in companion animals, equine and livestock. The Vetivex range of sevenlicensed products will continue to be manufactured by Ivex Pharmaceuticals inNorthern Ireland on behalf of Dechra. In 2004, the Vetivex range of productsachieved sales in excess of £1 million. Dechra will pay a cash consideration of £810,000 for the licenses and goodwill. Ian Page, Chief Executive, Dechra Pharmaceuticals said: "The market for fluid replacement therapy has seen consistent growth over recentyears. We believe that we can significantly improve the existing marketpenetration and profitability of the Vetivex range in this highly specialisedsector through exploiting Arnold's critical care expertise and dedicatedpharmaceutical sales team focus." Current trading within the Dechra Group remains encouraging with continued goodperformance from both our Pharmaceuticals and Services divisions. Enquiries:Ian Page, Chief Executive Fiona Tooley, DirectorSimon Evans, Group Finance Director Katie Dale, Senior Account ManagerDechra Pharmaceuticals PLC Citigate Dewe RogersonTel: + 44 (0) 1782 771100 Tel: +44 (0) 121 455 8370Mobile: 07775 642222 (IP) or 07775 642220 Mobile: 07785 703523 (FMT)(SE)www.dechra.com---------------- Editors Notes: About Dechra Pharmaceuticals PLCwww.dechra.comDechra Pharmaceuticals are specialists in the UK and international veterinaryand animal healthcare markets. Key to the Group's strategy is the development ofits veterinary pharmaceuticals portfolio. Quoted on the London Stock Exchange(under pharmaceuticals and biotech: Reuters: DPH.L), the business is split intotwo divisions: the pharmaceutical division which includes Arnolds VeterinaryProducts ("Arnolds"), Dales Pharmaceuticals ("Dales") and Dechra VeterinaryProducts ("DVP") (USA) and the services division which includes NationalVeterinary Services ("NVS"), NationWide Laboratories ("NWL"), CambridgeSpecialist Laboratory Services ("CSLS") and Vetcom Practice Management Systems("Vetcom"). Arnolds Veterinary ProductsArnolds is one of the most well respected and recognised brand names in theveterinary markets and holds a leading position in several specialist veterinarypharmaceutical sectors of the UK market such as endocrinology, local anaesthesiaand equine anti-inflammatory with strong positions in several other companionanimal sectors. Its pipeline in product development remains centred around:cardiology, endocrinology, respiratory and oncology. About Gambro ABwww.gambrobct.comGambro BCT, Inc. headquartered in Lakewood, Colorado, is a world leader in bloodbank technologies, automated blood collections and processing, pathogenreduction techniques and valued added blood and cell-based therapeutic services.Gambro BCT operates production facilities in the US and the UK, and has sales inmore than 90 countries. It is a wholly owned subsidiary of Gambro AB, a globalmedical technology and healthcare company. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
DPH.L